Just as skeptics were beginning to grudgingly acknowledge that marijuana’s cannabinoids do have medical benefits, a new wave or revolution is about to start if new research into the painkilling effects of the flavonoids unique to cannabis is anything to go by. A team of Canadian researchers has found that two flavonoids found in cannabis could be 30 times more powerful than aspirin, without the adverse effects associated with the conventional painkiller.
The work of these scientists seems poised to open another front in the medicinal potential of the cannabis plant which is enjoying growing popularity as the decades of prohibition get reversed in several states and jurisdictions.
Many plants have flavonoids, and these compounds give those plants their unique pigmentation. These compounds protect plants from diseases and UV radiation, and they also attract pollinators to the flowers of the plants.
More importantly, flavonoids have anti-inflammatory effects, and that is why many so-called superfoods are hailed as beneficial to people with inflammation in their bodies. The Canadian scientists have identified specific flavonoids that are only present in marijuana, and they have called them Cannaflavins.
Of particular interest is Cannaflavin A and Cannaflavin B which appear to be 30 times more potent than aspirin. Their healing effects were first hinted at by scientists at the University of London back in 1980.
However, there seems to be one major hurdle in the way of tapping the therapeutic value of these cannaflavins. These compounds occur in such small amounts that it could be hard to extract them in a way that makes economic sense.
This is where the work of the Canadian scientists comes in. The team, led by Tariq Akhtar (an assistant professor in the department of molecular and cellular biology at Guelph University), has developed and patented a novel technique through which the genes responsible for the formation of Cannaflavin A and B can be identified.
Their method then uses that genetic information to metabolically engineer the properties of those genes so that the therapeutic compounds can be obtained without having to grow vast amounts of cannabis plants.
The scientists have a lot of hope in these cannaflavins since they deal with inflammation at its source without any adverse effects. They therefore hope to conduct more research into these compounds now that the regulatory environment in Canada is supportive of such research.
Cannabis industry analysts believe that industry players like Green Hygienics Holdings Inc. (OTCQB: GRYN) and Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) could be very pleased because of the Guelph University research that shows there is still so much more that cannabis can offer in the medical arena.
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000
For more information please visit https://www.CNW420.com
Do you have a questions or are you interested in working with CNW420? Ask our Editor